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Hypertension, diabetes mellitus (especially type 2 diabetes mellitus), metabolic syndrome and obesity are rapidly growing
public health problems. Sympathetic nerve activation is observed in obesity, hypertension and diabetes mellitus, which have
strong genetic as well as environmental determinants. Reduced energy expenditure and resting metabolic rate are predictive
of weight gain, and the sympathetic nervous system participates in regulating energy balance through thermogenesis. The
thermogenic eﬀects of catecholamines in obesity have been mainly mediated via the β2- and β3-adrenergic receptors in humans.
Further, β2-adrenoceptors importantly inﬂuence vascular reactivity and may regulate blood pressure. Genetic polymorphistns
of the β-adrenoceptor gene have been shown to alter the function of several adrenoceptor subtypes and thus to modify the
response to catecholamine. β2-adrenoceptor polymorphisms (Arg16Gly, Gln27Glu, and Thr164Ile) have been studied in relation
to hypertension. Genetic variations in the β3-adrenoceptor (i.e. Try64Arg variant) are also associated with both obesity and
hypertension. However, the precise relationships of the polymorphisms of β2- and β3-adrenoceptor genes with sympathetic
nervous system activity, hypertension, and metabolic syndrome have not been fully clariﬁed. This paper will discuss the current
topics involving the inﬂuence of the sympathetic nervous system and β2- and β3- adrenoceptor polymorphisms in hypertension
and metabolic syndrome.
1.Introduction
Obesity, hypertension, and metabolic syndrome (type 2
diabetes mellitus) are major and growing health problems
and are known as high-risk factors for subsequent cardiovas-
cular and renal complications [1–3]. Obesity, hypertension,
diabetes, and metabolic syndrome are intimately associated
[4–6], and sympathetic nervous activation is frequently
observed in those conditions. Thus, sympathetic nerve acti-
vation may play a major role in the onset and development
of hypertension, obesity, and metabolic syndrome (diabetes
mellitus) as well as cardiovascular complications in patients
with hypertension, diabetes and obesity [2, 7].
The sympathetic nervous system plays an important role
in the regulation of energy expenditure. Reduced energy
expenditure and resting metabolic rate are predictive of
weight gain (obesity). The sympathetic nervous system
participates in regulating energy balance through thermoge-
nesis [8]. A large part of the sympathetic nervous system-
mediated energy expenditure takes place in skeletal muscle,
via the coupling of catecholamines with β2-adrenoceptors.
Catecholamines are also powerful regulators of lipolysis and
act via β1-, β2-, β3- (stimulatory), and α2- (inhibitory)
adrenoceptor subtypes in adipose tissue, where their role
becomes especially important during both exercise and
energy restriction, when increased need for fat as a fuel
exists. Thus, β-adrenoceptors play important roles in energy
expenditure and control body weight [9–13].
Recently, there is evidence that human hypertension and
obesity have strong genetic backgrounds [14–16]. Harrap
et al. reported that about 46% of the phenotype of systolic
blood pressure are determined genetically for hypertension
[17, 18]. Masuo et al. [18–22] have reported close rela-
tionships between β2- and β3-adrenoceptor polymorphisms2 International Journal of Hypertension
accompanying elevated sympathetic nervous activity, blood
pressure elevation (hypertension), weight gain (obesity),
and insulin resistance in a series of longitudinal study.
Many epidemiological studies on the relationships between
β-adrenoceptor polymorphisms, hypertension, obesity, and
diabetes (metabolic syndrome) have still been discordant.
This paper will discuss the current topics involving
the contribution of the sympathetic nervous system and
β2- and β3-adrenoceptor polymorphisms in the onset and
the development of hypertension and metabolic syndrome
(type 2 diabetes mellitus).
2.Subtypesof Adrenoceptors(Table 1)
The adrenoceptors (or adrenergic receptors) are a class of
G protein-coupled receptors which speciﬁcally bind their
endogenous ligands, the catecholamines (epinephrine and
norepinephrine). Many tissues possess these adrenoceptors,
and the binding of an agonist generally elicits a “typical”
sympathetic response (i.e., the ﬁght-or-ﬂight response).
Table 1 showstheeﬀectsofcatecholaminesboundtoadreno-
ceptors (Table 1) and these eﬀects on sympathetic nervous
activity are through α-a n dβ-adrenergic receptors.
There are several types of adrenergic receptors, but
there are two main groups: α-adrenoceptors (α1- and α2-
adrenoceptors) and β-adrenoceptors (β1-, β2-, and β3-
adrenoceptors).Table 1 alsosummariesthedistributionsand
functionsoftheα1-,α2-,β1-,β2-,andβ3-adrenoceptors[24,
25]. The α-receptors bind norepinephrine and epinephrine,
though norepinephrine has higher aﬃnity. Phenylephrine
is a selective agonist of the α-adrenoceptors (both α1-
and α2-receptors), thus phenylephrine is usually used to
investigate the α-adrenoceptors function. β-adrenoceptors
arelinkedtoGproteins,whicharelinkedtoadenylcyclase.β-
adrenoceptor agonists cause the intracellular elevation of the
second messenger cyclic AMP. Downstream eﬀects of cyclic
AMP include cyclic AMP dependent protein kinase, which
mediatestheintracellulareventsfollowinghormonebinding.
3. Sympathetic NervousActivityandInsulin
Resistance in Hypertension(Figure1)
Insulin resistance in hypertension has been well documented
in many epidemiological and clinical studies [8, 26, 27].
Several investigators have reported that chronic insulin
administrationelevatesbloodpressureinratsandinhumans
[28], although insulin also has eﬀects on vasodilation. In
addition, many clinical and epidemiological studies have
demonstrated the close relationships between sympathetic
nerve activity, insulin resistance and hypertension [19, 29–
32].
Landsberg and other investigators examined the eﬀect
of feeding and starvation on sympathetic nerve activity in
the cardiac tissue of animals, noting that feeding raised
sympathetic nerve activity, and starvation had the opposite
eﬀect [33–35]. Energy intake stimulates hyperinsulinemia
and sympathetic nerve activity resulting in blood pressure
elevations in a cycle to inhibit thermogenesis. Insulin-
mediated sympathetic nerve stimulation in obese subjects is
a compensatory mechanism aimed at restoring the energy
balance by increasing the metabolic rate [33]. Therefore,
hyperinsulinemia and insulin resistance in obese subjects
are all part of a response to limit further weight gain via
stimulating sympathetic nerve activity and thermogenesis
[28].
On the other hand, Julius et al. [36] have hypothe-
sized that increased sympathetic nerve activity in skeletal
musclecausesneurogenicvasoconstriction,therebyreducing
blood ﬂow to muscle and consequently inducing a state of
insulin resistance by lowering glucose delivery and uptake in
hypertension and obesity. Both blood pressure elevation and
weight gain may reﬂect a primary increase in sympathetic
n e r v o u st o n e .M a s u oe ta l .[ 30, 37] supported Julius’s
hypothesis. They described that high plasma norepinephrine
might predict future blood pressure elevations and weight
gain accompanying deterioration in insulin resistance
observed in HOMA-IR (homeostasis model assessments of
insulin resistance) [30, 37]. Rocchini et al. [38]r e p o r t e d
that clonidine prevented insulin resistance in obese dogs
over a 6-week period. Their results suggest that sympathetic
nerve activity might play a major role in the development of
insulin resistance accompanying blood pressure elevations.
Valentini et al. [39] reported attenuation of hemodynamic
and energy expenditure responses to isoproterenol infusion
in hypertensive patients, suggesting that sympathetic nerve
activity-induced hypertension may subsequently lead to the
development of obesity.
Many epidemiological studies showed close linkages of
beta2- and beta3-adrenoceptor polymorphisms with obesity,
hypertension, and the metabolic syndrome shown in Tables
2, 3,a n d4. Sympathetic nervous activity is related to
body weight or blood pressure through β-adrenoceptors.
Thus, close linkages between sympathetic nerve activity
and insulin resistance might depend on the β-adrenoceptor
polymorphisms. Thus, one could speculate that the strong
associations between β-adrenoceptor polymorphisms and
insulin resistance might provide evidence that heightened
sympathetic nerve activity followed by insulin resistance
might play a major role in hypertension and obesity, because
β-adrenoceptor polymorphisms might relate to insulin
resistance through heightened sympathetic nerve activity
(Figure 1).
4. Role of β-Adrenoceptor Polymorphisms in
Hypertension,Obesity,andDiabetes
The sympathetic nervous system plays an important role
in the regulation of energy expenditure and blood pressure
regulation. A large part of the sympathetic nervous system-
mediated energy expenditure takes place in skeletal muscle,
via the coupling of catecholamines with β2-adrenoceptors.
Catecholamines are also powerful regulators of lipolysis and
act via β1-, β2-, β3- (stimulatory), and α2- (inhibitory)
adrenoceptor subtypes in adipose tissue, where their role
becomes especially important during both exercise andInternational Journal of Hypertension 3
Table 1: Comparisons of adrenergic receptor subtypes.
Receptor type Agonist potency order Action sites Functions
α1-adrenoceptor norepinephrine≥ blood vessels of skim, gastrointestinal,
kidney vasoconstriction
epinephrine≫ ureter, uterus, urethral sphincter,
bronchioles smooth muscle contraction,
isoprenaline urinary bladder, contraction,
iris, blood vessels of erectile tissue, smooth muscle relaxation,
heart muscle, positive ionotropic eﬀect
salivary gland, increase in secretion,
adiposetissue, liver glycogenolysis and gluconeogenesis,
sweat glands, increase in secretion,
kidneys Na reabsorption
α2-adrenoceptor epinephrine> pancreas and inhibition of insulin secretion,
norepinephrine≫ induction of glucagon release, and
isoprenaline gastrointestinal tract contraction of sphincters
β1-adrenoceptor isoprenaline> heart, increase cardiac output,
Norepinephrine> kidneys (juxtaglomerular cells), increase renin release, and
Epinephrine adipose tissue lipolysis
β2-adrenoceptor isoprenaline> Bronchi, smooth muscle relaxation,
epinephrine  urinary sphincter, bladder wall, smooth muscle relaxation,
norepinephrine skeletal muscle, dilate arteries
adipose tissue, liver glycogenolysis and gluconeogenesis,
gastrointestinal tract, contract sphincters,
salivary glands, thickened secretions,
mast cells, and inhibit histamine release, and
kidneys (juxtaglomerular cells) increase renin release
β3-adrenoceptor
isoprenaline>
norepinephrine =
epinephrine
adipose tissue enhancement of lipolysis
Obesity Adrenoceptor
polymorphisms
DM2
↑RAA ↑Leptin
↑SNS activity
Structural eﬀects
Vasoconstriction
Na+ retention
↑Cardiac output
Hypertension
Hyperinsulinemia
Insulin resistance
Figure 1: Potential pathophysiological mechanisms by which obesity may contribute to hypertension (modiﬁed ﬁgure from [23]). RAAS:
renin-angiotensin-aldosterone system; SNS: sympathetic nervous system; OSA: obstructive sleep apnea; BRS, baroreﬂex sensitivity.4 International Journal of Hypertension
Table 2: Arg16Gly, β2-adrenoceptor polymorphisms: association with hypertension, metabolic syndrome (type2 diabetes: (DM)), and
obesity.
Authors Year Populations Subjects Associations with the polymorphism
Large et al. [40] 1997 Swedish 140 Caucasian women with a wide range
of obesity
Obesity
The Quebec Family Study [41] 2000 Canada Caucasian men and women Obesity, hyperlipidemia
Hayakawa et al. [42] 2000 Japanese 210 Japanese men from a population No association with obesity
Jia et al. [43] 2000 USA Caucasians (298 hypertensive versus 298
normotensive subjects)
No association with hypertension
Xie et al. [44] 2000 USA Black and white Americans (including
normotensive and hypertensive subjects)
No associations with hypertension
Candy et al. [45] 2000 English
England Black African men (including
192 hypertensive and 123 normotensive
men)
No association with hypertension
Cockcroft et al. [46] 2000 Caucasian 127 young normotensive men
Forearm vascular responses
(hypertension)
Meirhaeghe et al. [47] 2000 French 1195 middle-aged Caucasian from the
urban population
Obesity, if subjects carry Gln27Gln
Kato et al. [48] 2001 Japanese 842 hypertensive and 633 normotensive
subjects
BP levels (hypertension) in
normotensives
Bengtsson et al. [49] 2001 Swedish Hypertensive patients with and without
type 2 DM
Hypertension in subjects with DM
The Bogalusa Heart Study [50] 2002 USA 1151 Caucasian and Black Africans
children (including boys and girls)
Weight gain in males
Kim et al. [51] 2002 Korean type 2 DM patients Obesity, DM, hyperlipidemia
Chang et al. [52] 2002 Taiwanese type 2 DM patients Type 2 DM
V a nR o s s u me ta l .[ 53] 2002 Dutch 286 subjects with a signiﬁcant weight gain
over 7 years including men and women
Weight gain in men, but not in
women
The HERITAGE family study [54] 2003 Canada Sedentary black and white women Lower fat in obese white women
Pereira et al. [20] 2003 Brazilian 1576 ethnically mixed population
(including men and women)
Systolic BP, BMI
The Olivetti heart study [55] 2004 Italian 993 middle-aged men regardless of BP
levels or BMI
No association with obesity or
hypertension
Ikarashi et al. [56] 2004 Japanese type 2 diabetic patients Association with IR
Tafel et al. [57] 2004 Germany extremely obese children No association with obesity
Ellsworth et al. [58] 2005 USA Black and white American men and
women
BMI (obesity) in only men
Trombetta et al. [59] 2005 Brazilian Brazilian healthy women
Hypertension (blunted forearm
vasodilation response)
Masuo et al. [21] 2005 Japanese Nonobese, normotensive men
Weight gain, BP elevation,
obesity-HT
Masuo et al. [60] 2005 Japanese Nonobese, normotensive men Insulin resistance
Masuo et al. [61, 62] 2006 Japanese Normotensive men (including nonobese
and obese men)
Weight gain, blunted
leptin-sympathetic axis
Kurabayashi et al. [63] 2006 Japanese PCOS patients
Association with high prevalence of
PCOS Accompanying IR
Gjesing et al. [64] 2007 Dutch 7808 white subjects
No association with hypertension or
obesity
Masuo et al. [65] 2007 Japanese 219 nonobese, normotensive men Association with high SNA followed
by IR
BP: blood pressure; BMI: body mass index; HT: hypertension; DM: diabetes mellitus; IR: insulin resistance; PCOS: polycystic ovary syndrome; SNA:
sympathetic nervous activity.International Journal of Hypertension 5
Table 3: Gln27Glu, β2-adrenoceptor polymorphisms: association with hypertension, metabolic syndrome (type2 diabetes (DM)), and
obesity.
Authors [reference number] Year Populations Subjects Associations with the polymorphism
Large et al. [40] 1997 Swedish Caucasian women with a wide
range of obesity Association with obesity
Echwald et al. [66] 1998 Danish Caucasian juvenile-onset obese
men No association with obesity
Hellstr¨ om et al. [67] 1999 Swedish Caucasian men and women Association with obesity only in women
Kortner et al. [68] 1999 German Caucasian with morbid obesity No association with obesity
Xie et al. [44] 2000 USA Black and white Americans No associations with hypertension
The Quebec Family Study [41] 2000 Canada Caucasian men and women Association with obesity and
hyperlipidemia
Hayakawa et al. [42] 2000 Japanese 210 Japanese men from a
population No association with obesity
Candy et al. [45] 2000 England
Black African men (including
192 hypertensive and 123
normotensive men)
No association with hypertension
Meirhaeghe et al. [47] 2000 French 1195 middle-aged Caucasian in
the urban population Association with obesity in men
Kato et al. [48] 2001 Japanese 842 hypertensive and 633
normotensive subjects
Association with BP levels
(hypertension) in NT
Kawamura et al. [69] 2001 Japanese Japanese-Americans No association with obesity or DM
Ukkola et al. [70] 2002 USA 12 pairs of twins, Caucasians Association with weight gain (obesity)
Kim et al. [51] 2002 Korean Patients with type 2 DM Association with obesity, DM, and
hyperlipidemia
Gonzalez-Sanchez et al. [71] 2003 Spanish 666 Caucasian-based study
(including men and women) Association with obesity only in men
The HERITAGE family study [49] 2003 Canada Sedentary black and white men Association with lower fat in obese
white men
Pereira et al. [20] 2003 Brazilian
1576 ethnically mixed
population (including men and
women)
No association with systolic BP or BMI
The Olivetti heart study [55] 2004 Italian 993 middle-aged men (regardless
of BP levels or BMI)
No association with obesity or
hypertension
Tafel et al. [57] 2004 Germany Extremely obese children No association with obesity
Masuo et al. [21] 2005 Japanese Nonobese, normotensive men Association with BP elevation, but no
association with IR
Trombetta et al. [59] 2005 Brazilian Brazilian healthy women Association with hypertension (blunted
forearm vasodilation response)
Kurabayashi et al. [63] 2006 Japanese PCOS women Association with high prevalence of
PCOS accompanying IR
Gjesing et al. [64] 2007 Dutch 7808 white subjects No association with hypertension or
obesity
Masuo et al. [65] 2007 Japanese 219 nonobese, normotensive
men No association with IR
BP: blood pressure; BMI: body mass index; DM: diabetes mellitus; NIDDM: noninsulin-dependent diabetes mellitus; IR: insulin resistance; PCOS: polycystic
ovary syndrome; NT: normotensive subjects.
energyrestriction,whenincreasedneedforfatasafuelexists.
Stimulation of β-adrenergic receptors by the sympathetic
nervous system is a signiﬁcant physiological modulator of
pre- and postprandial energy expenditure [11–13] and total
daily energy expenditure [9, 10].
Recent studies show that β-adrenoceptors are poly-
morphic. Single nucleotide polymorphisms might have
functional consequences in terms of receptor activity and
regulation and hence may contribute to the pathophysiology
ofhypertensionandobesity.Ontheotherhand,therearefew
studies on the relationships between α-adrenoceptor poly-
morphisms, hypertension, obesity, and metabolic syndrome.
4.1. β1-Adrenoceptor Polymorphisms. The β1-adrenoceptor
is predominantly expressed in cardiac myocytes and adipose6 International Journal of Hypertension
Table 4: Trp64Arg, β3-adrenoceptor polymorphisms: association with hypertension, metabolic syndrome (type2 diabetes (DM)), and
obesity.
Authors [reference
number]
Year Populations Subjects Associations with the polymorphism
Clement et al. [76] 1995 French 185 subjects with
morbid obesity and Increased capacity of weight gain
94 subjects with
normal weight
Widen et al. [77] 1995 Finns
335 subjects including
207 non-DM and 128
patients with NIDDM
Insulin resistance
Walston et al. [78] 1995 Pima Indians 390 with NIDDM and
252 without NIDDM
Association with the early onset of
DM2
Fujisawa et al. [79] 1996 Japanese Patients with NIDDM Type 2 DM, weight gain (obesity)
Silver et al. [80] 1996 Nauruans 65 obese subjects with
NIDDM No association with DM2 or IR
Fujisawa et al. [81] 1997 Japanese Essential
hypertension patients
No association with IR during
hyperinsulinemia euglycemic glucose
clamp
Sakane et al. [82] 1997 Japanese 131 obese women
versus 218 controls Association with IR and obesity
Rissanen et al. [83] 1997 Finns
110 with NIDDM,
183 with IR, and 82
controls
No association with NIDDM or IR
McFarlane-Anderson
et al. [84]
1998 Jamaican Population study Association with hyperglycemia only
in women, but not in men
Grac´ ıa-Rubi et al.
[85]
1998 American Postmenopausal
women Association with IR
Janssen et al. [86] 1998 Dutch Postmenopausal
women Association with IR
Shiwaku et al. [87] 1998 Japanese Moderate overweight
men No association with obesity
Ongphiphadhanakul
et al. [88]
1999 Thais 76 men and 135
women
No association with IR assessed by
fasting insulin/glucose ratio
Pulkkinen et al. [89] 1999 Finns
185 untreated
non-DM and 119
untreated NIDDM
No association with IR or CHD in
both non-DM and NIDDM
Christiansen et al.
[90]
1999 Danish 196 dizygotic twins Association with lower insulin
secreting capacity
Kawamura et al. [69] 1999 Japanese-
American
Japanese living in
USA versus living in
Japan
Similar distribution between
Japanese-America and
Japanese-Japanese. Association with
IR in subjects with impaired oral
glucose tolerance test.
Stangl et al. [91] 2001 German 1000 with CHD and
1000 controls
No association with prevalence of
CHD or IR
Strazzullo et al. [92]
(The Olivetti
Prospective Heart
Study)
2001 Italian 979 population study No association with IR observed in
HOMA-IR
Ishii et al. [93] 2001 Japanese
196 young
normoglycemic men,
186 old
normoglycemic men,
and 122 old
hyperglycaemic men
No association with IR or NIDDM
Kurokawa et al. [94] 2001 Japanese meta-analysis in 6582
subjects BMI (obesity)International Journal of Hypertension 7
Table 4: Continued.
Authors [reference
number]
Year Populations Subjects Associations with the polymorphism
Ochoa et al. [95] 2004 Spanish 185 obese and 185
nonobese children BMI (obesity)
Porto et al. [96] 2004 Argentina
121 NT and 54 HT
from 934 high school
students
Association with central obesity, but
no association with IR
Tsai et al. [97] 2004 Taiwanese 299 pregnant women No association with gestational IR
Ellsworth et al. [58] 2005 USA
1179
African-Americans
and white-Americans
BMI (obesity)
M a s u oK ,e ta l .[ 21] 2005 Japanese Nonobese,
normotensive men BP elevation
Masuo et al. [62] 2006 Japanese 55 obese
normotensive men
Weight gain (obesity), BP elevation
(hypertension)
Højlund et al. [98] 2006 Danish 10 male twins No association between heterozygous
f o rT r p 6 4 A r ga n dI Ro rN I D D M
Tamaki et al. [99] 2006 Japanese
1416 population
study without HT,
DM, or
hyperlipidemia
No association with metabolic
syndrome
Morcillo et al. [100] 2008 Spanish 1020 population
study
Join association of alleles of -75A and
Arg64 with the risk of DM
Gjesing et al. [101] 2008 Danish 7605 population
study
Association with NIDDM and IR,
but no association with obesity
Dunajska et al. [102] 2008 Polish 284 postmenopausal
women
No association with metabolic
syndrome
BP: blood pressure; BMI: body mass index; DM: diabetes mellitus; NIDDM: noninsulin-dependent diabetes mellitus; DM2: type 2 diabetes mellitus; IR:
insulin resistance.
Table 5: Confounding variables considered to cause the discrepancy of the relationships between β-adrenoceptor polymorphisms and
phenotypes of hypertension and metabolic syndrome in obesity.
Variables [reference
number] Findings in the studies
Severity of obesity
[16, 57, 62, 76, 95]
In lean subjects, β2-AR polymorphisms linked to obesity and obesity-related hypertension, but in
obese subjects, β2- and β3-AR polymorphisms relate to obesity and obesity-related hypertension.
Morbid obesity is linked with β3-AR polymorphisms, but overweight or mild obesity is not associated
with those.
Gender diﬀerences [71]
Interaction between β1- and β2-AR polymorphisms with changes in BMI was observed in men only,
while in women an interaction between β1- and β3-AR polymorphisms was observed in a longitudinal
over a 24-year period large cohort study.
Ethnic diﬀerence [103, 104] Distributions of β-AR polymorphisms are diﬀerent in 8 diﬀerent ethnic populations.
Haplotype
[20, 58, 59, 105–107] Functions expressed of β-AR polymorphisms are diﬀerent due to the other β-AR polymorphisms.
AR: adrenoceptor; BMI: body mass index.
tissue, where its activation leads to increased heart rate
and contractility and stimulation of lipolysis, respectively.
The two most common β1-adrenoceptor polymorphisms
are Ser49Gly and Arg389Gly, with relative allele frequencies
of 0.85/0.15 and 0.70/0.30 in the Caucasian population,
respectively. The β1-adrenoceptor is a candidate gene for
obesity because of its role in catecholamine-mediated energy
homeostasis [72, 73]. For example, in obese individuals, the
degree of weight loss during a very low calorie diet has
been shown to correlate with changes in β1-adrenoceptor
protein concentration in adipose tissue [72]. A popula-
tion cohort of 761 women showed that women carrying
the Gly49 genotype had greater increases in BMI over15
years compared to those with the Ser49 genotype [73].
Conversely, the distribution of the Arg389Gly polymor-
phism is similar in lean and obese subjects [74] and in a
large cohort study including 3981 normotensive and 2518
hypertensive subjects [75]. The factors which might explain
the discrepancy of published data are shown in the later
section.8 International Journal of Hypertension
4.2. β2-Adrenoceptor Polymorphisms. The β2-adrenoceptor
is the dominant lipolytic receptor in white human adipose
tissue [13] and in skeletal muscle [12]. It also plays an
important regulatory role in the peripheral vasculature.
Genetic polymorphisms of the β2-adrenoceptor have been
associated with hypertension, obesity, and metabolic syn-
drome (diabetes mellitus). The most common polymor-
phisms are Arg16Gly, with an allele frequency of 0.40/0.60,
and Gln27Glu, with an allele frequency of 0.55/0.45, in
the Caucasian population. The Thr164Ile polymorphism is
rare, occurring in only 3 to 5% of the general Caucasians
population.
Studies of agonist stimulation in cultured cells demon-
strate that Gly16 receptors have a greater reduction in
numbers or enhanced downregulation when compared with
Arg16 whereas the Glu27 receptor is resistant to down
regulation when compared with the Gln27 variant [108]. A
number of clinical studies have investigated the impact of
these polymorphisms on vascular responsiveness [40, 109].
Gratzeetal.[110]foundthatyoungnormotensivewhitemen
homozygous for the Gly16 allele had higher blood pressure
and lower peripheral vasodilation after infusion of the β2-
agonist salbutamol. Similar results were obtained by Hoit et
al. [111] using the agonist terbutaline. On the other hand,
three studies investigating isoprenaline induced increase in
the limb blood ﬂow Thus, volunteers homozygous for Gly16
exhibited larger vasodilatory responses than did volunteers
homozygous for Arg16 [23]. Conﬂicting results have also
been published with regard to the eﬀects of genetic variants
on the sympathetic nervous system modulation of energy
expenditure. Bell et al. [112] reported that the response of
resting energy expenditure to nonspeciﬁc β-adrenoceptor
stimulation (with isoproterenol infusion) was not diﬀerent
between the 3 genotypes of Arg16Gly. Stob et al. [41] showed
that individuals carrying the Arg16Arg variant of the β2-
adrenoceptor gene have a reduced thermogenic response to
selective β2-adrenoceptor activation.
Associations of β2-adrenoceptor polymorphisms with
hypertension and metabolic syndrome have been reported in
many epidemiological studies but results are also discordant
(summarised in Tables 2 and 3).
4.3. β3-Adrenoceptor Polymorphisms. The β3-adrenoceptor,
which is mainly expressed in adipose tissue, diﬀers from
the β2-adrenoceptor in two ways: it has a lower aﬃnity for
catecholamines, and it resists desensitisation (i.e., downreg-
ulation). These characteristic diﬀerences might lead to the
diﬀerent eﬀects of catecholamine on β2-adrenoceptors and
β3-adrenoceptors. β3-adrenoceptors stimulate the mobi-
lization of lipids from the white fat cell and increase
thermogenesis in brown fat cell. Decreased function of β3-
adrenoceptor in white adipose tissue could slow lipolysis
and thereby cause the retention of lipids in fat cells.
Slow lipolysis may contribute strongly to visceral obesity
in human, and treatment of obese animal models with
selective β3-adrenergic agonists reduces fat stores most
eﬀectively [94, 113, 114]. Many epidemiological studies have
shown the strong relationships between β3-adrenoceptor
polymorphisms(mainlyTrp54Arg),hypertension,metabolic
syndrome, and obesity [78, 94, 113–117]( Table 4).
4.4. Confounding Variables Aﬀecting the Relationships of
β-Adrenoceptor Polymorphisms with Obesity, Hypertension,
a n dD i a b e t e s( Table 5). Tables 2, 3, 4,a n d5 show the
discordant contributions of β-adrenoceptor polymorphisms
to hypertension, metabolic syndrome (type 2 diabetes), and
obesity. Table 5 summarizes factors which might explain
the discrepancy of published data. Further, haplotypes of
polymorphisms have strong inﬂuence on β-adrenoceptor
function in each polymorphism [20, 58, 59, 105–107].
5. Conclusions
The role of the sympathetic nervous system β2- and β3-
adrenoceptor polymorphisms in hypertension, metabolic
syndrome (diabetes mellitus), and obesity is discussed
through a literature review. Sympathetic nervous system
activity and β-adrenoceptor polymorphisms (mainly β2-
and β3-adrenoceptor polymorphisms) might contribute to
the onset and maintenance of hypertension, metabolic
syndrome, and obesity; however, the ﬁndings have been
discordant. Further, few studies have been performed to
evaluate the relationship between β2- and β3-adrenoceptor
polymorphisms and sympathetic nervous system activity in
the same study. A better understanding for the relationships
of genetic background (polymorphisms) with sympathetic
nervous system activity as the cause for hypertension (blood
pressureelevation),metabolicsyndrome(insulinresistance),
and obesity (weight gain) might help for clinical treatment
for obesity-related hypertension and metabolic syndrome.
In fact, a number of studies have investigated genetic
polymorphisms as determinants of cardiovascular response
to antihypertensive drug therapy [103, 104]. But further
research on gene-drug interactions is necessary. In addition,
to clarify the pathogenesis and mechanisms may lead to
the prevention of hypertension and metabolic syndrome in
obesity.
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